Atara Biotherapeutics
ATRA
Performance
About Atara Biotherapeutics
Atara Biotherapeutics is a biopharmaceutical company focused on developing off-the-shelf, allogeneic T-cell immunotherapies. The company’s pipeline targets cancer, autoimmune diseases, and viral diseases with an emphasis on rapid, scalable manufacturing and a versatile CAR T-like platform. Headquartered in the United States, Atara emphasizes first-in-class therapies that can be delivered rapidly from inventory to patients in need.
Recent News
FDA Again Rejects Atara, Pierre Fabre's Cell Therapy for Epstein-Barr Virus
Hippocratic AI Announces New Senior Executive Appointments
Ongoing Regulatory Uncertainty Means Innovation Is Now Higher Risk
Wave To Work Alone on RNA Editor as AATD Picture Becomes Clearer
FDA Reconsiders Ebvallo Cell Therapy After Surprise Rejection
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
FDA Clears IND for Cellenkos' CK0802, First‑in‑Class Treg Therapy for Steroid‑Refractory GVHD
Healthcare Moves: A Monthly Summary of Hires, Exits and Layoffs
Atara, Pierre Fabre's Cell Therapy to Get Another Shot at FDA Approval
Recent Deals
No recent deals for this company.